검색 상세

Treatment of direct oral anticoagulants in patients with liver cirrhosis and portal vein thrombosis

  • 주제(키워드) Anticoagulants , Portal vein , Thrombosis , Liver cirrhosis
  • 주제(기타) Gastroenterology & Hepatology
  • 설명문(일반) [Chun, Ho Soo; Choe, A. Reum; Lee, Minjong; Kim, Hwi Young; Yoo, Kwon; Kim, Tae Hun] Ewha Womans Univ, Dept Internal Med, Coll Med, Seoul, South Korea; [Chun, Ho Soo; Choe, A. Reum; Lee, Minjong; Kim, Hwi Young; Yoo, Kwon; Kim, Tae Hun] Ewha Womans Univ, Dept Internal Med, Med Ctr, Seoul, South Korea; [Cho, Yuri] Natl Canc Ctr, Ctr Liver & Pancreatobiliary Canc, Res Inst & Hosp, Goyang, South Korea
  • 등재 SCIE, SCOPUS, KCI등재
  • OA유형 gold, Green Published
  • 발행기관 KOREAN ASSOC STUDY LIVER
  • 발행년도 2021
  • 총서유형 Journal
  • URI http://www.dcollection.net/handler/ewha/000000183683
  • 본문언어 영어
  • Published As http://dx.doi.org/10.3350/cmh.2021.0109
  • PubMed https://pubmed.ncbi.nlm.nih.gov/34130370

초록/요약

Although patients with cirrhosis are known to be in a state of "rebalance" in that pro-and anticoagulant factors increase the risk for both bleeding and thrombosis, the prevalence of portal vein thrombosis (PVT) in patients with cirrhosis can be up to 26%. Therefore, physicians should consider anticoagulation for the prevention and management of PVT in patients with cirrhosis who are at high risk of PVT. Vitamin K antagonist or low molecular weight heparin is suggested as the standard treatment for PVT in cirrhosis. With the advent of new direct-acting oral anticoagulants (DOACs), there is a paradigm shift of switching to DOACs for the treatment of PVT in patients with cirrhosis. However, the safety and efficacy of DOACs in the treatment of PVT was not well-known in patients with cirrhosis. Therefore, this review focused on the current knowledge about the efficacy, safety concerns, and hepatic metabolism of DOACs in patients with cirrhosis and PVT. (Clin Mol Hepatol 2021;27:535-552)

more